Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease (AI4PKD)
The primary aim of this observational exploratory study is to develop AI-based image processing methods to advance the characterization of Polycystic Kidney Disease using medical images and associated clinical data, including:
- AI-based fully automatic segmentation techniques for the accurate identification of kidneys, liver, and cysts, with a focus on AI interpretability and robustness;
- advanced AI-based image processing techniques allowing to identify new imaging biomarkers, including through the use of radiomics, to characterize ADPKD tissue microstructure and therefore stage the disease and monitor and predict disease progression and response to therapy;
- multiparametric models including image-based radiomic features alongside clinical and laboratory data to stratify ADPKD patients and predict ADPKD progression over time.
The study will also have the secondary aim of validating the novel techniques against gold standard (manual) methods, when available.
Study Overview
Status
Detailed Description
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most prevalent hereditary kidney disease, affecting 12.5 million people worldwide in all ethnic groups. ADPKD is caused by a gene mutation in either PKD1 or PKD2, that leads to the formation and growing of multiple fluid-filled cysts in the kidneys and often the liver, leading to chronic kidney injury and ultimately end-stage renal disease. In ADPKD, kidney function may remain normal for several decades and is therefore not fully informative. The identification of early biomarkers able to accurately monitor and predict disease progression in order to take prompt action and select targeting treatment options is urgently needed. Total kidney volume has been recognized as a prognostic biomarker to select patients for clinical trials and is acknowledged by the scientific community as a relevant biomarker to monitor disease progression and response to therapy, and to predict ADPKD course. Total kidney volume can be quantified using medical images, such as Ultrasound, Computed Tomography, and Magnetic Resonance Imaging (MRI). Renal non-contrast enhanced MRI, denoted by high resolution and with no need for contrast agents or ionizing radiation, is the most suited to monitor total kidney volume progression over time and clearly detect kidney cysts. Since many ADPKD patients also have polycystic livers, total liver and liver cyst volume may provide additional relevant information.
Total kidney, liver, and cyst volume measurements are based on kidney segmentation, which is generally performed by manual contouring, an operator-dependent and time-consuming task requiring dedicated expertise. Automatic or semi-automatic methods for kidney and cysts segmentation have been proposed in the past based on traditional approaches and artificial intelligence (AI) techniques. However, the low explainability and the need of large and curated datasets allowing to obtain accurate and generalized models have so far hampered their wide adoption in clinical research. A fully automatic segmentation method for the accurate identification of kidneys, liver, and cysts would be highly desirable.
Beyond kidney, liver, and cyst volume quantification, the characterization of non-cystic renal tissue may provide additional relevant information on ADPKD pathophysiology. Few years ago, a contrastenhanced CT study revealed the presence of peritubular interstitial fibrosis in the non-cystic component of ADPKD kidneys, that was associated with renal function and its decline over time, confirmed more recently by an independent study on dynamic contrast-enhanced T1-weighted MRI. Advanced image processing techniques, such as radiomics, which aims to compute high throughput information from radiological images for the characterization of tissue spatial heterogeneity, show potential to characterise tissue microstructure. Preliminary attempts on ADPKD patients were performed on T1-weighted and T2-weighted MRI scans. Besides, radiomics could be helpful to build multiparametric stratification and prediction models including image-based features.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
BG
-
Ranica, BG, Italy, 24020
- Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
For this study the following pseudonymised medical images and associated clinical data will be used:
- Images and clinical data acquired in the context of ADPKD studies promoted by IRFMN
- Images and clinical data coming from the CYSTic1 study repository, required in accordance with CYSTic1 Sponsor (University of Sheffield, UK) guidance
- Images and clinical data coming from the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) public dataset (https://repository.niddk.nih.gov/studies/crisp1/), required in accordance with the CRISP guidance.
Description
Inclusion Criteria:
- Patients with ADPKD
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Patients
ADPKD patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Image-processing methods
Time Frame: From image acquisition to study end at 10 years
|
Develop AI-based image processing methods using medical images and associated clinical data from ADPKD studies ad repositories
|
From image acquisition to study end at 10 years
|
Collaborators and Investigators
Investigators
- Study Director: Giuseppe Remuzzi, M.D., Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Publications and helpful links
General Publications
- He X, Hu Z, Dev H, Romano DJ, Sharbatdaran A, Raza SI, Wang SJ, Teichman K, Shih G, Chevalier JM, Shimonov D, Blumenfeld JD, Goel A, Sabuncu MR, Prince MR. Test Retest Reproducibility of Organ Volume Measurements in ADPKD Using 3D Multimodality Deep Learning. Acad Radiol. 2024 Mar;31(3):889-899. doi: 10.1016/j.acra.2023.09.009. Epub 2023 Oct 3.
- Kline TL, Edwards ME, Fetzer J, Gregory AV, Anaam D, Metzger AJ, Erickson BJ. Automatic semantic segmentation of kidney cysts in MR images of patients affected by autosomal-dominant polycystic kidney disease. Abdom Radiol (NY). 2021 Mar;46(3):1053-1061. doi: 10.1007/s00261-020-02748-4. Epub 2020 Sep 17.
- Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ; CRISP Investigators. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 Nov;92(5):1206-1216. doi: 10.1016/j.kint.2017.03.026. Epub 2017 May 20.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ciliopathies
- Urogenital Diseases
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genetic Diseases, Inborn
- Congenital Abnormalities
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Kidney Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
Other Study ID Numbers
- AI4PKD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.